Two Sigma Investments
CYCN icon

Two Sigma Investments’s Cyclerion Therapeutics CYCN Stock Holding History

Two Sigma Investments’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-41,555
Closed -$52.8K – 4643
2025
Q4 		$52.8K Buy
41,555
+28,262
+213% +$50.5K ﹤0.01% 3928
2025
Q3 		$30.6K Buy
+13,293
New +$36.1K ﹤0.01% 3570
2022
Q2 		– Sell
-2,120
Closed -$47K – 2596
2022
Q1 		$47K Sell
2,120
-4,759
-69% -$115K ﹤0.01% 2493
2021
Q4 		$237K Sell
6,879
-12,651
-65% -$598K ﹤0.01% 3810
2021
Q3 		$1.2M Buy
19,530
+11,845
+154% +$775K ﹤0.01% 2447
2021
Q2 		$599K Sell
7,685
-161
-2% -$10.1K ﹤0.01% 2938
2021
Q1 		$438K Buy
7,846
+2,457
+46% +$185K ﹤0.01% 3052
2020
Q4 		$330K Buy
+5,389
New +$367K ﹤0.01% 2784
2020
Q1 		– Sell
-4,906
Closed -$267K – 3240
2019
Q4 		$267K Buy
+4,906
New +$458K ﹤0.01% 3270

Other funds holding CYCN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KA
Kovack Advisors Ft. Lauderdale, Florida $1.87B AUM 29.51% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Two Sigma Investments's CYCN Position: Q1 2026 in Review

Two Sigma Investments sold out of Cyclerion Therapeutics (CYCN) in Q1 2026, closing a stake of 41,555 shares — an estimated $52.8K sold.

Two Sigma Investments first reported a position in CYCN in Q4 2019 and held it in 9 quarters. The position peaked at $1.2M in Q3 2021. 17 funds tracked by Wall St. Rank hold CYCN as of Q1 2026.

  • Two Sigma Investments reported no remaining Cyclerion Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Investments sold 41,555 Cyclerion Therapeutics shares in Q1 2026, an estimated $52.8K.
  • Two Sigma Investments first reported a position in Cyclerion Therapeutics in Q4 2019 and held it in 9 quarters.
  • Two Sigma Investments's Cyclerion Therapeutics position peaked at $1.2M in Q3 2021.
  • 17 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.